Hale Bopp Study

  • Research type

    Research Study

  • Full title

    The prospective assessment of long-term outcome of deferred coronary lesions based on fractional flow reserve (HALE BOPP) study

  • IRAS ID

    259623

  • Contact name

    S Watkins

  • Contact email

    stuart.watkins@nhs.net

  • Sponsor organisation

    Azienda Ospedaliero Universitaria di Ferrara Cona

  • Clinicaltrials.gov Identifier

    NCT03079739

  • Duration of Study in the UK

    5 years, 5 months, 31 days

  • Research summary

    Treatment of myocardial ischemia with coronary intervention through the skin (PCI) in addition to optimal medical therapy reduces adverse events on the heart. However, less than half of the patients have non-invasive ischemic evaluation before revascularization. Fractional flow reserve (FFR) can determine the significance of the blood circulation of a coronary lesion by measuring the pressures of the coronary and aortic vessels at the extremities during maximum blood flow. Previous studies have shown that FFR guidance revascularization improves clinical outcomes, quality of life and economic management. However, the reliability and safety of FFR assessment in different settings than stable coronary artery dysfunction are unclear. There are no data available from other clinically used devices. The HALE BOPP registry is a study that does not involve any particular medical intervention except the observation of what normally happens in normal medical practice initiated prospectively on all patients undergoing coronary angiography in which at least 1 lesion was evaluated by FFR.

  • REC name

    West of Scotland REC 1

  • REC reference

    19/WS/0046

  • Date of REC Opinion

    14 May 2019

  • REC opinion

    Further Information Favourable Opinion